ARASENS Trial: Should darolutamide now be added to androgen-deprivation therapy and docetaxel in patients with metastatic, hormone-sensitive prostate cancer?

Detalles Bibliográficos
Autor principal: Kumar, Naveen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Uroscan
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9380449/
https://www.ncbi.nlm.nih.gov/pubmed/35983110
http://dx.doi.org/10.4103/iju.iju_81_22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9380449/
https://www.ncbi.nlm.nih.gov/pubmed/35983110
http://dx.doi.org/10.4103/iju.iju_81_22

Ejemplares similares